The initial public offering (IPO) of Claris Lifesciences Ltd has been subscribed 0.50 times so far. The IPO received bids for 5,390,484 shares against the issue size of 10,789,474 shares on offer.
The high networth individual (HNIs) category as well as the retail portion were subscribed more than once, while qualified institutional bidders (QIB) have not evinced much interest in the IPO so far.
The IPO had been extended till December 2, that is, today as the public issue received a lukewarm response amid a steep fall in the market following the bribes-for-loans scam that came to light last week. Furthermore, Claris also revised its IPO price band to Rs 223 to Rs 248 from Rs 278 to Rs 293 earlier.
The book running lead managers to the issue are Enam Securities, Edelweiss Capital, JM Financial and ICICI Securities.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app